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Background/aim: Helicobacter pylori is a major health problem. One of the therapeutic approaches is administration of antibody against
H. pylori. The methylotrophic Pichia pastoris is a suitable host for expression of recombinant antibody fragments. The aims of this study
were the expression and the evaluation of camelid nanobody in the yeast Pichia pastoris.
Materials and methods: The camelid-derived heavy-chain antibody (nanobody) against the UreC subunit of urease from H. pylori
was subcloned in the pPink-HC shuttle vector and transferred into Escherichia coli TOP10. After digestion and purification, the shuttle
vector was transformed in the PichiaPink expression system. The expression was evaluated in an in vitro system.
Results: The yield of the nanobody expressed in P. pastoris was estimated to be 5 mg/L as compared to 2 mg/L expressed by E. coli.
The nanobody was purified and binding affinity to the UreC antigen was evaluated using ELISA. Neutralization abilities of the two
nanobodies expressed in yeast and E. coli were compared. The yeast-expressed nanobody specifically detected recombinant UreC and
inhibited urease activity with high efficiency.
Conclusion: The results suggest attribution of the enhanced quality and quantity of the nanobody produced in P. pastoris to better
posttranslational modification and folding in the yeast cell.
Key words: Pichia pastoris, Helicobacter pylori, urease, nanobody expression

1. Introduction
Helicobacter pylori is a major human pathogen. It has been
estimated that half of the world’s population is infected
with this bacterium (1,2). H. pylori colonizes human gastric
mucosa and causes gastritis, duodenal ulcers, and even
gastric cancer (1–3). Treatment of H. pylori infection with
antibiotics leads to increased risk of antibiotic resistance.
The high cost of available treatment measures and the
increased number of reported relapses generate the need
for new alternative therapeutic approaches (4). Urease
enzyme is an important virulence factor since it allows
for survival under acidic conditions and the possibility of
H. pylori colonization (5,6). The UreC subunit of urease
enzyme exists in catalytic sites, showing great vaccine
potential and antibody development for treatment of H.
pylori infection (4,7). Classic antibodies have functional
limitations such as interaction with the immune system
and inadequate pharmacokinetics or tissue accessibility.
Camels and sharks produce heavy-chain antibodies (8,9).
The variable domain of heavy-chain antibodies (VHH),
* Correspondence: slmousavi@shahed.ac.ir

also called nanobodies, is the smallest (~15 kDa) available
intact antigen-binding fragment. The heavy-chain
antibodies are less antigenic as compared to conventional
antibodies (4,9–11). High solubility and low aggregation
propensity, easy cloning, suitability for display systems,
and resistance to temperature and pH are other advantages
of nanobodies (9,10,12). Nanobodies’ efficiency for
the treatment of intestinal infections such as retroviral
intestinal infections has been investigated (13). The
VHH against the UreC subunit of urease was previously
produced and expressed in Escherichia coli TOP10 (4).
Yeast expression systems have emerged as heterologous
expression hosts for several reasons. As eukaryotic
systems, they are capable of performing many eukaryotespecific posttranslational modifications such as folding,
glycosylation, and disulfide bond formation (14,15).
Among yeasts, Pichia pastoris has become increasingly
popular in recent years for protein expression (14). This
methylotrophic yeast has a promoter derived from the
alcohol oxidase 1 (AOX1) gene, which is one of strongest
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and most tightly regulated promoters (16,17). The length
of the oligosaccharide chains added posttranslationally
to protein in P. pastoris is much shorter than those in S.
cerevisiae; thus, glycoproteins generated in P. pastoris are
more suitable for therapeutic use (17). P. pastoris yeast
has the ability of large-scale production of heterologous
proteins in fermenters (18).
In order to increase the production and inhibitory
effects of VHH antibodies, in this study a nanobody against
the UreC subunit of urease was produced in a P. pastoris
strain by the PichiaPink expression system. The yields of
VHH antibody expressed in the PichiaPink expression
system and E. coli were compared. In vitro neutralization
of the nanobody in both the yeast and the bacterium was
also investigated.
2. Materials and methods
This experimental study was done at Shahed University’s
biotechnology laboratory.
2.1. Expression and purification of recombinant UreC
antigen
pET28a harboring the ureC gene was obtained from our
previous study (7). The recombinant antigen induced
with isopropyl β-D-1-thiogalactopyranoside (IPTG) was
expressed in modified E. coli strain BL21(DE3) (from
Novagen) at 37 °C. The UreC protein containing the His-tag
was purified by Ni-NTA affinity agarose chromatography
under both native and denatured conditions.
2.2. VHH amplification and subcloning
The VHH gene fragment was amplified from the
pET28a vector by PCR method using the EcoRI
restriction site and Kozak sequence in the forward
primer (5’-CTAGAATTCGAAACGATGGAGGTGCAG
CTGSWGSAKTCKG-3’) and the KpnI restriction sites
in the reverse primer (5’-CTAGGTACCTGA CACCACC
ACCACCACCACGGAGACGGTGACCWGGG-3’).
The PCR product was purified using a PCR product
purification kit (Bioneer, South Korea). VHH fragments
and the pPink-HC vector were digested with EcoRI and
KpnI and purified before proceeding for ligation reaction.
Ligation was performed with T4 DNA ligase overnight
at 12 °C and the mixture was transformed into freshly
prepared competent E. coli TOP10 cells. Positive clones
were confirmed with colony PCR and restriction digestion
analysis.
2.3. Transformation and screening of P. pastoris
In order to promote integration into the P. pastoris genome,
the pPink-HC vectors carrying the VHH gene were
linearized with Vha4641 enzyme (isoschizomer of AflII)
and then purified by ethanol precipitation. The PichiaPink
Expression strain was grown at 30 °C and 250 rpm in YPD
medium until an A600 nm of 1.5 was reached. The cells were
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then harvested and washed two times with sterile ice-cold
water and resuspended in 2 mL of 1 M sterile ice-cold
sorbitol. The cells were centrifuged and resuspended in 60
µL of ice-cold, sterile 1 M sorbitol. Approximately 10 µg of
linearized construct was added to the cell suspension in
an electroporation cuvette and incubated on ice for 5 min.
The cells were pulsed in the electroporator according to
the manufacturer’s instructions, and then 1 mL of ice-cold
YPDS medium was added to the cuvette and incubated
at 28 °C. Next, 300 µL of the cell mixture was taken from
the cuvette and spread on minimal dextrose agar and
incubated at 30 °C until distinct colonies were formed.
White colonies were picked up and plasmid integration
into the yeast genome was confirmed by PCR.
2.4. Nanobody expression and analysis
For expression of the nanobody, 10 mL of BMGY medium
(buffered glycerol-complex medium: 1% yeast extract; 2%
peptone; 100 mM potassium phosphate, pH 6.0; 1.34%
yeast nitrogen base (YNB); 0.0004% biotin; 1% glycerol)
was inoculated with isolated clones and grown at 30 °C
with vigorous shaking at 250 rpm for 48 h. The cells were
then transferred into 100 mL of BMGY medium and
grown at 30 °C and 250 rpm until OD600 0.6 was reached.
The cultures were centrifuged at 1500 × g for 5 min at
room temperature. The cells were resuspended in 40 mL of
BMMY medium (buffered methanol-complex medium: 1%
yeast extract; 2% peptone; 100 mM potassium phosphate,
pH 6.0; 1.34% YNB; 0.0004% biotin; 0.5% methanol) in
order to induce the expression of the nanobody. Cultures
were grown for 96 h at 30 °C and 250 rpm with the addition
of methanol to a final concentration of 0.5% v/v every 24
h. The cells were harvested by centrifugation at 2000 × g
for 10 min. The pellet was resuspended in breaking buffer
(50 mM sodium phosphate, pH 7.4; 1 mM PMSF; 1 mM
EDTA; 5% glycerol) and homogenized with acid-washed
glass beads. The mixture was centrifuged at 13,000 × g for
20 min and clear supernatant was collected.
2.5. SDS-PAGE analysis and dot blot technique
The expression of the nanobody was studied on 15%
SDS-PAGE under reducing conditions. For dot blotting,
1 µg of nanobody expressed in yeast was transferred
to nitrocellulose paper. Recombinant UreC antigen
containing His-tag fusion at the N-terminal was used
as the positive control. The membranes were dried and
blocked with 3% BSA in PBST [10 mM phosphate buffer,
pH 7.4; 150 mM NaCl; 0.05% (v/v) Tween-20]. After
16 h the membranes were washed and the membrane
containing yeast-produced nanobody was incubated with
10 µg/mL of UreC antigen solution for 2 h at 37 °C with
mild agitation. Antibody–antigen reaction was detected
with a 1/5000 dilution of HRP conjugated with anti-His
Tag antibody (Roche, Germany) and DAB (Bangalore
GeNei, India) as a substrate.
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2.6. Affinity measurement of nanobody against UreC
antigen
VHH nanobody binding affinity to the UreC antigen
containing His-tag was evaluated using ELISA testing as
described by Beatty et al. (19). Various concentrations
(5, 10, 15, and 20 µg/mL) of nanobody produced in yeast
were coated on a 96-well microplate and incubated at 4
°C overnight. After washing six times with PBST, the wells
were blocked with 5% skim milk in PBST and incubated
for 1 h at 37 °C, and the UreC antigen was added at 5, 10,
15, and 20 µg/mL concentrations and incubated at 4 °C
overnight. After washing with PBST, 100 µL of a 1/10,000
dilution of HRP-conjugated anti-His antibody was added
and incubated for 1 h at 37 °C. The immune reactivity was
developed with 100 µL of 3,3’,5,5’-tetramethylbenzidine
chromogenic substrate. The reaction was stopped with
3 N H2SO4 and optical density was measured at 450 nm
using an auto microplate reader. Each experiment was
performed in triplicate.
2.7. Comparison of VHH expression in PichiaPink and
E. coli
VHH nanobody expression in E. coli strain BL21(DE3)
was induced with 1 mM IPTG for 16 h at 28 °C at an OD600
of 0.5 as described previously. In order to compare the
yield of VHH nanobody expressed in PichiaPink and E.
coli, a test was designed using an equal amount of yeast
and bacterial cells. After determining the number of cells
in a specific volume of the medium, an equal number of
bacterial and yeast cells were broken and their expression
levels were analyzed using SDS-PAGE.
2.8. In vitro neutralization of nanobody expressed in
yeast and bacteria
The H. pylori reference strain (Sydney strain: SS1) was
cultured in Brucella agar medium (Difco). Colonies were
transferred into brain-heart infusion broth and kept under
microaerophilic conditions for 24 h at 37 °C. From those
colonies, 109 cfu was mixed with 0–20 µg concentrations of
each UreC VHH in PBS and incubated in microplate wells
for 16 h at 4 °C. BSA was used as a negative control, and 100
µL of PBS buffer containing 10% urea and 15 g/L phenol red
(pH 7.0) was added to each well and wells were incubated
at room temperature for 30 min. Color development was
measured at OD550 nm and measurements were repeated
every 30 min for 3 h. Inhibition percentage was calculated
by the following equation:
% inhibition = [(enzymatic activity without nanobody
– enzymatic activity with nanobody) / (enzymatic activity
without nanobody)] × 100.
Each experiment was performed in triplicate.
2.9. Statistical analysis
Data were reported as mean ± SD and statistical analysis
was performed using one-way ANOVA (SPSS 16.0). The

significance (P < 0.01) of differences were assessed by post
hoc comparison of means using the lowest significant
differences (Duncan).
3. Results
3.1. Construction and transformation of the recombinant
vector
The gene coding for the UreC VHH nanobody fragment
was amplified by PCR with introduction of EcoRI and
KpnI restriction sites. The yield of the VHH gene amplified
was 1.5 µg. The gene encoding the camelid-derived heavychain antibody was ligated into the pPink-HC shuttle
vector and transformed into PichiaPink strain 1 by
electroporation. The recombinant clones were confirmed
by colony PCR (Figure 1).
3.2. Expression and purification of nanobody in
PichiaPink
Expression analysis on SDS-PAGE showed an 18-kDa
protein band (Figure 2a). White clones had high VHH
expression compared to pink clones. Figure 2b shows
the nanobody purification using the native PAGE
electrophoresis system. VHH production was further
confirmed by dot blot analysis (Figure 2c).
3.3. Affinity determination
The affinity of the purified VHH nanobody for the UreC
antigen was tested by ELISA. The affinity of VHH for the
UreC antigen was increased significantly compared to the
control (P < 0.05). As shown in Figure 3, the affinity of

Figure 1. PCR confirmation of the recombinant clones. The
recombinant clones were screened using the colony PCR
technique. A 400-bp band related to the nanobody was observed
on agarose gel. Lanes 1–4: PCR products, Lane 5: negative
control, Lane 6: DNA ladder mix.
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Figure 2. Production, purification, and dot blot analysis of VHH produced in PichiaPink. a) SDS-PAGE gel stained with Coomassie
blue, Lane 1: negative control (cell lysate before induction), Lane 2: VHH expressed in PichiaPink, Lane 3: molecular weight marker. b)
Purification of recombinant VHH, Lane 1: molecular weight marker, Lane 2: the purified VHH protein. c) Dot blot analysis of VHH,
Lane 1: positive control (the specific reaction of the anti-His tag antibody with bacterial nanobody), Lane 2: the specific reaction of the
anti-His tag antibody with yeast nanobody, Lane 3: negative control.

Figure 3. Binding assay of nanobody with recombinant UreC antigen.
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VHH for the UreC antigen was increased in the presence
of a high concentration (20 µg/mL) of the antigen. There
was a significant difference between the increase of VHH
affinity for UreC in the presence of 5, 10, 15, and 20 µg/mL
antigen concentrations (P < 0.01).
The estimated affinity of the purified nanobody for UreC
was (9.09 ± 0.3) × 10–8 M.
3.4. Comparison of bacterial and yeast nanobody
expression and neutralization
The expression level of the nanobody in P. pastoris was
observed to be more than that of E. coli. Total yields of
nanobody obtained from P. pastoris and E. coli were 5 and
2 mg/L, respectively (Figure 4).
To compare the efficacy of nanobody produced in E.
coli and PichiaPink, H. pylori was incubated with serial
dilutions of the UreC VHH nanobody. The inhibition
percentage was assayed with color measurement at 550
nm. The minimum concentration of nanobody required
to inhibit urease activity was 20 µg/mL. The maximum
inhibitory effect of VHH nanobody produced in E. coli
and PichiaPink at this concentration was 61% and 86%,
respectively (Figure 5). Statistically significant differences
of the maximum inhibitory effect of VHH nanobody
between the nanobody produced in E. coli and in
PichiaPink were observed (P < 0.01).

Figure 4. Yield comparison of nanobody produced in PichiaPink
and E. coli. Lane 1: Molecular weight marker, Lane 2: nanobody
expressed in PichiaPink, Lane 3: nanobody expressed in E. coli.

Figure 5. Inhibition of urease activity by nanobodies produced in Pichia pastoris
(P-nanobody) and E. coli (E-nanobody) against UreC antigen.
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4. Discussion
Although antibiotic therapy often leads to the
improvement of H. pylori infection treatment, it fails in
20% of cases and contributes to the development of drug
resistance. Researchers have made efforts to achieve new
approaches as alternatives to antibiotic-based therapies
(20). Previous studies investigated L-ascorbic acid, copper
ions, and acetohydroxamic acid as inhibitors of the urease
activity of H. pylori. However, these compounds have
several problems, such as toxicity and instability (21).
Antibodies could be one of the most effective measures
against H. pylori. Antibodies that specifically recognize
H. pylori antigens not only deal with infection but also
overcome the development of bacterial drug resistance
(7). Antibodies against urease are present in patients
with H. pylori infections. Monoclonal and single-chain
variable fragment (scFv) antibodies against urease have
been produced in some studies (22–24). Nagata et al.
(23) showed 100% inhibition potency of urease activity
by MAb. Similar results were reported by Ikeda et al.
(22), who showed 82% inhibitory effect of MAb on the
enzymatic activity of urease. Since MAbs are not very
stable and poorly immunogenic, the development of a
new class of antibodies seems necessary (4,25). Previously,
VHH nanobody against UreC recombinant protein was
produced using an E. coli host (4). For better expression
and posttranslational modifications, in this study VHH
with high affinity and specificity was produced in P.
pastoris against UreC and 5 mg/L VHH expression was
achieved in P. pastoris as compared to 2 mg/L in E. coli.
Many antibody fragments were reported to be expressed in
P. pastoris (26). In 1997, two single-chain antibodies, antiCD7 and anti-DMI, were produced in E. coli at a level of
0.25 mg/L, whereas these fragments were produced in P.
pastoris at 60 mg/L and 100–250 mg/L, respectively (27,28).
Similarly, expression of functional rabbit antirecombinant
human leukemia inhibitory scFv in P. pastoris was 100-

fold more than its expression in E. coli (28,29).The use of
P. pastoris yeast for production of anti-MUC1 VHH was
reported at the 10–15 mg/L level (25). VHH produced in
P. pastoris inhibited urease activity by 86%, whereas 61%
inhibition in the urease activity was observed by E. coliproduced nanobody. In other words, the inhibition due to
VHH produced in P. pastoris was significantly increased
(25%) compared to that of E. coli-produced nanobody
(P < 0.05). Nagata et al. and Ikeda et al. (23,22) reported
100% and 82% urease inhibition by monoclonal antibody,
respectively. The aforementioned studies were focused
on purified urease for inhibition assay, whereas in our
studies H. pylori cells are used as a target for inhibition
assay of urease activity where the natural 3D structure of
the enzyme is maintained in the whole cell. This can be
considered as an advantage of the present work.
The results suggest attribution of the enhanced quality
and quantity of the nanobody produced in P. pastoris to
better posttranslational modification and folding in the
yeast cell.
The findings suggest that nanobody produced in
yeast against the UreC subunit of H. pylori is specifically
successful in inhibition of H. pylori infection. H. pylori is
associated with various gastric diseases such as superficial
gastritis, chronic atrophic gastritis, gastric cancer, or peptic
ulcer; therefore, vaccines or prophylactic antibodies could
reduce the enormous human and economic consequences
of H. pylori infection and improve health and quality of life.
Thus, the nanobody produced in the present study
could lead to a therapeutic and prophylactic approach
in the management of H. pylori-associated disease and
should be further investigated.
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